Nat Clin Pract Gastroenterol Hepatol. 2009;6(5):267-278. A thorough history and assessment of allergic diseases is a vital part of the evaluation of a patient with suspected EoE because of the ...

The 3 main treatments for EoE are medication, dietary therapy, or mechanical dilation of the esophagus. Patients should be evaluated individually to address their most problematic complaints first, ...

In the US, veterans with atopic diseases were more likely to develop eosinophilic esophagitis (EoE) than those without, with food allergies showing the strongest association. Overall, 26% (288,193) ...

Researchers at Children's Hospital of Philadelphia (CHOP) identified a potential new therapeutic target for eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.

Please provide your email address to receive an email when new articles are posted on . The researchers used data from patients aged 1 to 18 years in the TriNetX Collaborative Network. Early diagnosis ...

PHILADELPHIA (WPVI) -- Allergic reactions come in all varieties. One can even trigger a digestive disease which makes it hard to swallow. It's known as EOE - Eosinophilic Esophagitis. For more than 30 ...

While dupilumab's use has been extended to children under 12, benralizumab shows no benefit to patients with eosinophilic esophagitis (EoE). Despite high hopes, a drug that wipes out the namesake cell ...

Researchers at Children's Hospital of Philadelphia (CHOP) identified a potential new therapeutic target for eosinophilic esophagitis (EoE), a chronic allergic inflammatory disease of the esophagus.

HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE).

Philadelphia, August 15, 2025 – Researchers from Children’s Hospital of Philadelphia (CHOP) and Children’s Hospital Colorado have found that better control of chronic eosinophilic esophagitis ...

Worm-inspired biotech Holoclara has had a busy year. After announcing a $16 million series A round in June, the Pasadena, California, company has now dosed the first patient in a phase 1 trial of its ...

Study found that stiffness of the esophagus could serve as an important biomarker for disease progression and indicate which patients may benefit the most from current therapies PHILADELPHIA, Aug. 15, ...